Q-RNA Overview
- Founded
-
1996
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$11M
Q-RNA General Information
Description
Provider of biotechnology. The company engages in discovery and development of RNA ligands, specialized RNA molecules that bind and functionally interact with desired targets. They can be used to detect the presence (or absence) of virtually any organic or inorganic target with extreme sensitivity and specificity and have applications in medicinal diagnosis and the treatment of disorders and diseases. The company is currently focused on diseases such as Alzheimer's, epilepsy and Parkinson's disease.
Contact Information
Website
www.q-rna.com
Formerly Known As
InVitro Diagnostics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
- 3960 Broadway
- Suite 407
- New York, NY 10032
- United States
Q-RNA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 17-Nov-2006 | $11M | 00.00 | 0000 | Completed | Generating Revenue |
| 2. Later Stage VC (Series B) | 02-Jun-2003 | 00.00 | 00.00 | 000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 08-Aug-2001 | $700K | $700K | 00.000 | Completed | Generating Revenue |
Q-RNA Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 |
Q-RNA Patents
Q-RNA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20050214805-A1 | Immunoglobulin replicase fusion for use in diagnosing nervous system and prion disorders | Inactive | 10-Nov-2003 | 000000000 | 00 |
| US-20060024736-A1 | Methods of detection employing immuno-q-amp technology | Inactive | 10-Nov-2003 | 000000000 | |
| US-20060199194-A1 | Methods of detection using immuno-q-amp technology | Inactive | 10-Nov-2003 | 0000000000 | |
| US-20080241840-A1 | Using tau protein specific immunoglobulin/single-stranded dna fusion as evaluative tool in diagnosis alzheimer's disease | Inactive | 10-Nov-2003 | 0000000000 | |
| AU-2003304543-A1 | Prion protein dye conjugates and methods of use | Inactive | 15-Oct-2003 | G01N33/6896 |
Q-RNA Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Abraham Grossman Ph.D | Founder | ||
| William McIntosh | Chief Executive Officer |
Q-RNA Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Double D Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Durand Venture Associates | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Wheatley Partners | PE/Buyout | Minority | 000 0000 | 000000 0 |